Drug Discontinuation and Persistent Symptoms Among Initiators of Bio-Originator and Biosimilar anti-Tumor Necrosis Factor Drugs in Inflammatory Bowel Disease: Real-World Contemporary Data From the CAnadian Network for Advanced Interdisciplinary Methods/CIRC Registry.

ABSTRACT:

Background and aims

Biosimilars and their originator anti-tumor necrosis factor drugs remain important in inflammatory bowel diseases (IBDs). We assessed drug discontinuation, IBD symptoms, and quality of life (QoL) in adults after initiating infliximab and adalimumab bio-originators or biosimilars.

Methods

Six Canadian IBD sites enrolled initiators of these drugs, between January 2019 and February 2024. We determined drug discontinuation, concomitant medications, and symptoms and QoL (using the Short Inflammatory Bowel Disease Questionnaire and 5-level EuroQol-5D) at 12 months after initiating therapy, and assessed differences between bio-originator and biosimilar users.

Results

We evaluated 205 initiators of infliximab (N = 151) or adalimumab (N = 54) who had comple

SUBMITTER: Oketola B 

PROVIDER: S-EPMC12681726 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature